Severe SARS-CoV-2 patients develop a higher specific T-cell response.

Julie DemaretGuillaume LefèvreFanny VuottoJacques TrauetAlain DuhamelJulien LabreuchePauline VarletArnaud DendoovenSarah StablerBenoit GachetJules BauerBrigitte PrevostLaurence BocketEnagnon Kazali AlidjinouMarc LambertCécile YelnikBertrand MeresseLaurent DubuquoyDavid LaunaySylvain DubucquoiDavid MontaigneEloise WoitrainFrançois MaggiottoMohamed Bou SalehIsabelle TopVincent ElsermansEmmanuelle JeanpierreAnnabelle DupontSophie SusenThierry BrousseauJulien PoissyKarine FaureMyriam Labalettenull null

Published in: Clinical & translational immunology (2020)

IFNγ T-CoV-Spot assay is a reliable method to explore specific T cells in large cohorts of patients. This test may become a useful tool to assess the long-lived memory T-cell response after vaccination. Our study demonstrates that SARS-CoV-2 patients developing a severe disease achieve a higher adaptive immune response.

Keyphrases

sars cov
end stage renal disease
immune response
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
early onset